Treatment of low-risk myelodysplastic syndromes by erythroprotein and its derivatives

被引：0

作者：

Villeval, Jean-Luc ^{[1
]}

Sainty, Danielle ^{[2
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Inst Paoli Calmettes, Marseille, France

来源：

HEMATOLOGIE | 2006年 / 12卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10 / 11

页数：2

共 50 条

[31] Efficacy of growth factors compared to chemotherapy in low-risk myelodysplastic syndromes. [J].

Golshayan, A ;

Fu, AZ ;

Kattan, MW ;

Brown, S ;

Maciejewski, JP ;

Sekeres, MA .

BLOOD, 2005, 106 (11) :713A-714A

[32] HEPCIDIN AND ERYTHROFERRONE (ERFE) ARE NOT CORRELATED IN THE ANEMIA OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS) [J].

Redondo, S. ;

Oarbeascoa, G. ;

Moran Jimenez, M. J. ;

Domingo, A. ;

Munoz Linares, C. ;

Moreno Carralero, M. I. ;

Bellon, J. M. ;

Del Campo Rincon, J. F. ;

Diez-Martin, J. L. ;

Font, P. .

HAEMATOLOGICA, 2018, 103 :183-184

[33] Moving low-risk myelodysplastic syndromes from humans to mice: is it truly that simple? [J].

Coriu, Daniel ;

Stancioaica, Maria -Camelia .

HAEMATOLOGICA, 2024, 109 (01) :8-10

[34] The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances [J].

Randall, Michael P. ;

DeZern, Amy E. .

CANCER JOURNAL, 2023, 29 (03) :152-159

[35] Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes [J].

Golshayan, Ali-Reza ;

Jin, Tao ;

Maciejewski, Jaroslaw ;

Fu, Alex Z. ;

Bershadsky, Boris ;

Kattan, Michael W. ;

Kalaycio, Matt E. ;

Sekeres, Mikkael A. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (02) :125-132

[36] Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment [J].

Remacha, Angel F. ;

Arrizabalaga, Beatriz ;

Bueno, Javier ;

Munoz, Juan ;

Bargay, Joan ;

Pedro, Carme .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02) :339-340

[37] High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms [J].

Xie, Zhuoer ;

Komrokji, Zena ;

Otterstatter, Michael ;

Zhang, Ling ;

Moscinski, Lynn C. ;

Al Ali, Najla H. ;

Sallman, David ;

Lancet, Jeffrey E. ;

Dezern, Amy E. ;

Sekeres, Mikkael A. ;

Komrokji, Rami S. ;

Gillis, Nancy ;

Padron, Eric .

BLOOD, 2024, 144 :355-355

[38] Part 3: Myelodysplastic syndromes-Treatment of low-risk patients without the 5q deletion [J].

Rodrigues Pereira Velloso, Elvira Deolinda ;

Meira Magalhaes, Silvia Maria ;

Lopes Ferrari Chauffaille, Maria de Lourdes ;

Buzzini, Renata ;

Bernardo, Wanderley Marques .

HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (03) :267-273

[39] Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes [J].

Latagliata, R. ;

Oliva, E. N. ;

Volpicelli, P. ;

Carmosino, I. ;

Breccia, M. ;

Vincelli, I. ;

Alati, C. ;

Napoleone, L. ;

Vozella, F. ;

Nobile, F. ;

Alimena, G. .

ACTA HAEMATOLOGICA, 2008, 120 (02) :104-107

[40] Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry [J].

Grinblatt, Davld L. ;

Narang, Mohit ;

Malone, James M., III ;

Sweet, David A. ;

Dunne, Tim S. ;

Sullivan, Kristen A. .

BLOOD, 2008, 112 (11) :581-581

← 1 2 3 4 5 →